A comparison of the clinical effects of treatment for sepsis and septic shock with conservative methods or continuous hemodiafiltration (CHDF) using an AN69ST membrane

Abstract

Here we assessed clinical effects of continuous hemodiafiltration (CHDF) using the AN69ST membrane for the treatment of sepsis/septic shock. This study included 56 patients diagnosed with sepsis/septic shock at the Department of Critical Care at the Emergency and Clinical Care Center, Tokyo Women’s Medical University Medical Center East between June 1, 2015 and November 30, 2017. Of them, 38 patients were treated with the AN69ST membrane (AN69ST group) and 18 were treated without the AN69ST membrane (non-AN69ST group). AN69ST membranes were used in all cases receiving CHFD, and endotoxin absorption therapy was not administered. In the AN69ST group, the mean blood pressure at baseline and after 72 hours was 66mmHg[interquartile range (IQR): 58–82mmHg] and 92mmHg (IQR: 82–108mmHg), respectively. In the non-AN69ST group, these values were 60mmHg (IQR: 55–72mmHg) and 87mmHg (IQR: 81–102mmHg), respectively. Despite the increase in blood pressure observed in both groups, the difference was not statistically significant. Similarly, there were no differences observed in pulse, PaO2/FIO2 ratio, blood lactic acid, catecholamine index, urine volume, or total infusion volume between the groups. Studies of additional cases are warranted to investigate survival in patients with sepsis/septic shock.